Cargando…

SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia

Sodium–glucose co-transporter-2 (SGLT2) inhibitors decreased cardiovascular (CV) events and improved renal outcomes in CV safety studies in type 2 diabetes melitus (T2DM) patients at high CV risk. Canagliflozin also improved kidney outcomes in diabetic kidney disease in the Canagliflozin and Renal E...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fernandez-Fernandez, Beatriz, Sarafidis, Pantelis, Kanbay, Mehmet, Navarro-González, Juan F, Soler, María José, Górriz, Jose Luis, Ortiz, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Editorial Comments
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577767/ https://www.ncbi.nlm.nih.gov/pubmed/33123352 http://dx.doi.org/10.1093/ckj/sfaa198

Ejemplares similares

EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors
por: Fernández-Fernandez, Beatriz, et al.
Publicado: (2023)

Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2020)

Blood pressure targets in CKD 2021: the never-ending guidelines debacle
por: Carriazo, Sol, et al.
Publicado: (2022)

Optimizing the timing of nephrology referral for patients with diabetic kidney disease
por: Martínez-Castelao, Alberto, et al.
Publicado: (2020)

Benchmarking CKD: incidence of CKD in a European country with low prevalence of CKD and kidney replacement therapy
por: Ortiz, Alberto
Publicado: (2022)

Kidney disease and electrolytes in COVID-19: more than meets the eye
por: Carriazo, Sol, et al.
Publicado: (2020)

Blood pressure targets in patients with chronic kidney disease: MDRD and AASK now confirming SPRINT
por: Sarafidis, Pantelis, et al.
Publicado: (2020)

Aguascalientes: one of the hottest chronic kidney disease (CKD) hotspots in Mexico and a CKD of unknown aetiology mystery to be solved
por: Villalvazo, Priscila, et al.
Publicado: (2021)

The dirty little secret of urate-lowering therapy: useless to stop chronic kidney disease progression and may increase mortality
por: Gonzalez-Martin, Guillermo, et al.
Publicado: (2020)

Could Pirfenidone Also be Effective in Treating Intestinal Fibrosis?
por: Latella, Giovanni, et al.
Publicado: (2020)

Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA)
por: Sarafidis, Pantelis, et al.
Publicado: (2023)

The assessment of hypertension in kidney transplant patients: time to change our approach?
por: Demiray, Atalay, et al.
Publicado: (2021)

Klotho, the elusive kidney-derived anti-ageing factor
por: Sanchez-Niño, Maria Dolores, et al.
Publicado: (2019)

Increase in the global burden of chronic kidney disease: might it be attributable to air pollution?
por: Copur, Sidar, et al.
Publicado: (2022)

Visit-to-visit blood pressure variability and risk of dementia in chronic kidney disease patients: why are blood pressure changes so important in cognitive functions?
por: Yavuz, Furkan, et al.
Publicado: (2022)

SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA
por: Mark, Patrick B, et al.
Publicado: (2023)

Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2019)

Renal artery stenting in the correct patients with atherosclerotic renovascular disease: time for a proper renal and cardiovascular outcome study?
por: Theodorakopoulou, Marieta P, et al.
Publicado: (2022)

The chaos of hypertension guidelines for chronic kidney disease patients
por: Castillo-Rodriguez, Esmeralda, et al.
Publicado: (2019)

A promising tool: triglyceride–glucose index to stratify the risk of cardiovascular events in chronic kidney disease
por: Yildirim, Fatma, et al.
Publicado: (2022)

Kidney replacement therapy patients with COVID-19 in the vaccine era: what do we need to know?
por: Vehbi, Sezan, et al.
Publicado: (2022)

GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
por: Górriz, José Luis, et al.
Publicado: (2020)

Intravenous fluid therapy in accordance with kidney injury risk: when to prescribe what volume of which solution
por: Kanbay, Mehmet, et al.
Publicado: (2022)

Should we continue to use renin–angiotensin–aldosterone system blockers in patients with COVID-19?
por: Copur, Sidar, et al.
Publicado: (2022)

Long-term effect of COVID-19 infection on hemodialysis patients: Should we follow hemodialysis patients more closely?
por: Demiray, Atalay, et al.
Publicado: (2021)

What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer?
por: Evans, Marc, et al.
Publicado: (2019)

Chronodisruption: A Poorly Recognized Feature of CKD
por: Carriazo, Sol, et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease
por: Górriz, Jose Luis, et al.
Publicado: (2020)

SGLT2 inhibitors and renal complications in type 1 diabetes
por: Petrie, John R
Publicado: (2020)

Sunglasses to hide behind may also prevent melanoma of the eyes
por: Dhomen, Nathalie, et al.
Publicado: (2021)

Editorial: Management of Patients With Non-dialysis Dependent Chronic Kidney Disease (ND-CKD)
por: Provenzano, Michele, et al.
Publicado: (2022)

SGLT-2 inhibitors in nephrotic-range proteinuria: emerging clinical evidence
por: Kalay, Zeynepgul, et al.
Publicado: (2022)

Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease
por: Fernandez-Prado, Raul, et al.
Publicado: (2020)

Phosphate, Microbiota and CKD
por: Favero, Chiara, et al.
Publicado: (2021)

Tirzepatide and prevention of chronic kidney disease
por: Bosch, Catalina, et al.
Publicado: (2022)

The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD
por: Noel, J. Ariana, et al.
Publicado: (2022)

COVID-19 and its impact on the kidney and the nephrology community
por: Soler, María José, et al.
Publicado: (2021)

Antioxidant Roles of SGLT2 Inhibitors in the Kidney
por: Llorens-Cebrià, Carmen, et al.
Publicado: (2022)

Cardiovascular disease in older women with CKD
por: Radley, Alice, et al.
Publicado: (2023)

Ensuring Indigenous co-leadership in health research: a Can-SOLVE CKD case example
por: Woods, Cathy, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_miusnrs8homqteccbk2m5bj2l1